Diurnal timing and volume of physical activity in relation to metabolic syndrome in US adults: a population-based cohort study
August 25, 2025 / metabolic syndrome risk / physical activity timing / morning exercise benefits / NHANES cohort study / metabolic health outcomes
Morning and midday-afternoon physical activity are associated with lower odds of metabolic syndrome (MetS) in U.S. adults. Higher total activity volume further reduces risk, while late afternoon-evening or nighttime activity may be linked to worse metabolic outcomes.
Can metabolic syndrome substantially increase Parkinson’s risk?
A large UK Biobank study found that metabolic syndrome increases the risk of developing Parkinson’s disease by 40%. The findings suggest a dose-dependent relationship and highlight the importance of managing metabolic health to potentially reduce neurodegenerative risk.
Wegovy Is Now the Second FDA-Approved Treatment for MASH Fibrosis
August 25, 2025 / Wegovy MASH approval / GLP-1 liver treatment / metabolic liver disease / FDA fibrosis therapy / obesity and liver health
Wegovy received FDA accelerated approval as the second treatment for MASH fibrosis, showing significant improvement in liver health and metabolic function. It offers both anti-inflammatory and weight loss benefits, supporting its use alongside diet and exercise for liver disease management.
Twin Health Announces $53M Investment as AI Digital Twin Unlocks Sustainable Diabetes and Obesity Outcomes While Reducing Medications
Aug 21, 2025 / AI digital twin / diabetes reversal technology / obesity management AI / personalized metabolic health / GLP-1 alternative care
Twin Health secured $53M to expand its AI-driven digital twin platform, which personalizes real-time care for diabetes and obesity. Clinical results show sustainable outcomes—including A1C reduction and weight loss—while minimizing reliance on costly medications like GLP-1s.
Digital twin startup Twin Health secures $53M, nears $1B valuation
August 22, 2024 / AI digital twin / metabolic disease reversal / Twin Health funding / personalized diabetes care / obesity management platform
Twin Health raised $53M in Series E funding, nearing a $1B valuation, to expand its AI-powered digital twin platform that personalizes care for metabolic conditions like type 2 diabetes and obesity using continuous, real-time biomarker and lifestyle data.
Orforglipron Phase 3 Data: Dr. Michael Weintraub Reviews ATTAIN-1 and ACHIEVE-1 Findings
August 21, 2025 / orforglipron phase 3 / oral GLP-1 agonist / obesity treatment oral / cardiometabolic outcomes GLP-1 / type 2 diabetes weight loss
Phase 3 trials show orforglipron, an oral GLP-1 receptor agonist, induces significant weight loss and cardiometabolic improvements. Though less effective than injectables, its oral format may improve access and adherence, especially for patients avoiding injections. GI side effects remain comparable.
Metabolic Dysregulation and Female Infertility: A Systematic Review of Hormonal and Reproductive Outcomes From Recent Clinical Trials
August 24, 2025 / female infertility metabolism / PCOS fertility treatment / hormonal imbalance women / insulin resistance ovulation / metabolic syndrome reproductive health
This systematic review of clinical trials (2015–2024) shows that metabolic disorders like PCOS, insulin resistance, and obesity significantly impair female fertility. Targeted interventions—pharmacological, dietary, and lifestyle—can improve hormonal balance, ovulation, and pregnancy outcomes in affected women.
The microbiome is associated with obesity-related metabolome signature in the process of aging
August 25, 2025 / gut microbiome aging / obesity metabolome signature / linoleic acid metabolism / microbiota lipid pathways / metabolic aging mice
This study reveals that aging-related metabolic changes, especially in lipid pathways like linoleic acid metabolism, are significantly influenced by the gut microbiome. Aged mice with microbiota showed more metabolomic shifts than germ-free counterparts, underscoring microbiome’s role in metabolic aging.
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
August 19, 2025 / VK2735 obesity trial / GLP-1 GIP dual agonist / oral weight loss drug / Viking Therapeutics Phase 2 / metabolic disorder treatment
Viking Therapeutics’ Phase 2 trial of oral VK2735 showed significant weight loss in obese patients. The dual GLP-1/GIP receptor agonist met all endpoints, demonstrating both efficacy and a favorable safety profile over 13 weeks of daily dosing.
Signos Unveils First Ever FDA-Cleared Glucose Monitoring Breakthrough for Weight Management, Enabling Millions of Americans to Take Control of Their Health
August 20, 2024 / glucose monitoring weight / metabolic health insights / FDA cleared Signos / Dexcom biosensor AI / real-time weight management
Signos has launched the first FDA-cleared, over-the-counter glucose monitoring system for weight management. By integrating Dexcom’s Stelo biosensor with AI-driven insights, it empowers users to track metabolic responses in real time, supporting personalized weight loss and metabolic health.
Dr Jitendra Singh calls for scientifically authenticated information on obesity & metabolic disorders
August 19, 2025 / obesity India awareness / metabolic disorders prevention / Ozempic Mounjaro caution / lifestyle disease education / Indian obesity data
Dr. Jitendra Singh emphasized the urgent need for scientifically validated information on obesity and metabolic disorders in India, highlighting rising rates, the importance of prevention, lifestyle interventions, and caution with emerging weight loss drugs like Ozempic and Mounjaro.
Characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes
August 23, 2025 / MASLD / type 1 diabetes / liver steatosis biomarkers / lipidomics insulin resistance / ceramides obesity
In type 1 diabetes, individuals with MASLD show elevated BMI, insulin resistance, and increased circulating lipids—particularly ceramides, diacylglycerols, and triacylglycerols—highlighting a distinct lipidomic signature linked to steatosis but not fibrosis in liver disease progression.
Best Treatment Approach to Newly Classified MASLD Yet to Be Defined
August 25, 2025 / MASLD / liver disease treatment / MASH therapies / cardiovascular risk / resmetirom semaglutide
MASLD, a reclassified multisystem liver disease, significantly raises risks for cardiovascular, renal, and oncologic conditions. While resmetirom and incretin-based therapies show promise, optimal treatment strategies—especially for MASH—remain undefined and require further clinical investigation.
FDA gives conditional approval to Wegovy for some liver patients
August 22, 2025 / Wegovy / MASH treatment / FDA approval / liver fibrosis / semaglutide therapy
The FDA granted conditional approval for Wegovy (semaglutide) to treat MASH in patients with moderate to advanced fibrosis, marking a milestone in liver disease care. Approval is contingent on confirmatory trial data validating its efficacy and safety.
People With Weight-Related Chronic Liver Disease Have a New Treatment Option
August 19, 2025 / Wegovy / MASH treatment / liver fibrosis / semaglutide injection / FDA approval
The FDA has expanded Wegovy’s approval to include treatment for MASH in adults with moderate to severe liver fibrosis. This marks a significant advancement in managing weight-related liver disease, offering improved access and liver-specific benefits via semaglutide.
Wegovy Approved for Noncirrhotic MASH With Moderate, Advanced Liver Fibrosis
August 19, 2025 / Wegovy / MASH treatment / liver fibrosis / semaglutide approval / ESSENCE trial
The FDA granted accelerated approval to Wegovy (semaglutide) for treating noncirrhotic MASH with moderate to advanced fibrosis. Phase 3 ESSENCE trial data showed significant improvements in liver histology and weight loss, supporting its role in managing MASH-related liver damage.
Empowering patients to shape the future of MASH care
August 24, 2025 / MASH advocacy / liver disease research / Dr Stephen Harrison / patient empowerment / clinical trials
In honor of the late Dr. Stephen Harrison, a leading MASH researcher, a new patient advocacy fellowship empowers individuals to influence liver disease research, care, and policy—addressing key barriers in diagnosis, clinical trial participation, and health system engagement.
FDA Approves Wegovy to Treat Severe Liver Disease
August 25, 2025 / Wegovy / MASH treatment / liver fibrosis / semaglutide approval / ESSENCE trial
The FDA has approved Wegovy (semaglutide) for treating MASH with moderate-to-advanced liver fibrosis. Backed by ESSENCE trial results, this GLP-1 therapy significantly improves liver health and may help prevent progression to cirrhosis and liver failure when combined with lifestyle changes.
FDA Grants Accelerated Approval of Semaglutide for Treatment of MASH With Liver Fibrosis
August 19, 2025 / semaglutide / MASH treatment / liver fibrosis / Wegovy approval / ESSENCE trial
The FDA has granted accelerated approval of semaglutide (Wegovy) for adults with MASH and moderate-to-advanced liver fibrosis, based on phase 3 ESSENCE trial data showing significant histologic improvements. Long-term outcomes will be confirmed through ongoing clinical trials.
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
August 19, 2025 / Wegovy / MASH treatment / liver fibrosis / GLP-1 approval / ESSENCE trial
The FDA has granted accelerated approval to Wegovy (semaglutide) for treating MASH with liver fibrosis, making it the first GLP-1 therapy authorized for this indication. Approval is based on ESSENCE trial results demonstrating significant liver health improvements.